Felcht M, Hillen U, Klemke C-D
Klinik für Dermatologie, Venerologie und Allergologie, UMM - Universitätsmedizin Mannheim Medizinische Fakultät Mannheim, Ruprechts-Karls-Universität Heidelberg, Exzellenzzentrum für Dermatologie des Landes Baden-Württemberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
Klinik für Dermatologie und Venerologie, Vivantes Klinikum Berlin Neukölln, Rudower Str. 48, 12351, Berlin, Deutschland.
Hautarzt. 2017 Sep;68(9):696-701. doi: 10.1007/s00105-017-4020-6.
Primary cutaneous lymphomas can be diagnosed when the clinical symptoms, histology, immunohistology and molecular biological changes are characteristic of primary cutaneous T or B‑cell lymphomas; however, in many cases not all of the changes are typical of a primary cutaneous lymphoma especially in the early stages; therefore, the diagnosis of a primary cutaneous lymphoma can be a challenge. This is especially true for the Sézary syndrome, which can initially prove to be difficult to differentiate from reactive erythroderma; therefore, the main focus of this review is the diagnostics of Sézary syndrome. The review also summarizes the clinical heterogeneity and describes the classical histological and immunohistochemical changes for the diagnosis of Sézary syndrome. Recent data from different multicenter, international studies by the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer (EORTC) on dermatological alterations of the skin and the detection of Sézary cells in blood are addressed. The detection of Sézary cells in the blood still remains a challenge despite improved molecular boiological and cytogenetic characterization of tumor cells. The latest studies of the EORTC group particularly identified CD158k, MYC, MNT, DNM, TWIST1, EPHA4 and PLS3 as valuable markers for the differentiation of reactive erythroderma but which are not yet part of the standard diagnostics of Sézary syndrome. Further studies are required to see if these markers can be used in the routine clinical application.
当临床症状、组织学、免疫组织学及分子生物学改变具有原发性皮肤T或B细胞淋巴瘤的特征时,可诊断原发性皮肤淋巴瘤;然而,在许多情况下,尤其是在疾病早期,并非所有改变都具有原发性皮肤淋巴瘤的典型特征;因此,原发性皮肤淋巴瘤的诊断可能具有挑战性。这在蕈样肉芽肿综合征中尤为如此,该综合征最初可能难以与反应性红皮病相鉴别;因此,本综述的主要重点是蕈样肉芽肿综合征的诊断。该综述还总结了临床异质性,并描述了用于诊断蕈样肉芽肿综合征的经典组织学和免疫组化改变。文中还提及了欧洲癌症研究与治疗组织(EORTC)皮肤淋巴瘤特别工作组开展的不同多中心国际研究中关于皮肤的皮肤病学改变及血液中蕈样肉芽肿细胞检测的最新数据。尽管肿瘤细胞的分子生物学和细胞遗传学特征有所改善,但血液中蕈样肉芽肿细胞的检测仍然是一项挑战。EORTC小组的最新研究特别确定CD158k、MYC、MNT、DNM、TWIST1、EPHA4和PLS3作为鉴别反应性红皮病的有价值标志物,但这些标志物尚未成为蕈样肉芽肿综合征标准诊断的一部分。需要进一步研究以确定这些标志物是否可用于常规临床应用。